What is Hangzhou Tigermed Consulting Co. Ltd?
, Ltd, together with its subsidiaries, provides contract research organization services in the People's Republic of China and internationally.
HNGZY · Verdict
Moderate reward · moderate risk
HNGZY stands out on cash flow and volatility, but watch the profitability signal.
Based on 88% data coverage
HNGZY · Verdict
11% free-cash-flow margin
Above average
6% net margin · 3% ROE
Rev +8.2% CAGR · earnings -48.0%
Model-based scoring. For information only — not financial advice.
, Ltd, together with its subsidiaries, provides contract research organization services in the People's Republic of China and internationally. It operates through Clinical Trial Solutions; and Clinical-related and Laboratory Services segments. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 3.44B, and a P/E ratio of 26.7x.
The scoring profile indicates limited reward potential at this time, with valuation and momentum offering the most support. Risk indicators are moderate, consistent with typical market exposure.
For informational purposes only. Not financial advice.